Implementing access to medication assisted treatment in a drug treatment court: Correlates, consequences, and obstacles

References

• Andrews, D. A., & Bonta, J. (1995). The level of service inventory-revised. Toronto, Canada: Multi-Health Systems.
   Google Scholar
• Belenko, S., Hiller, M., & Hamilton, L. (2013). Treating substance use disorders in the criminal justice system. Current Psychiatry Reports, 15(11), 414. doi:10.1007/s11920-013-0414-z
   PubMed Web of Science ®Google Scholar
• Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 71(7), 821–826. doi:10.1001/jamapsychiatry.2014.366
   PubMed Web of Science ®Google Scholar
• Coviello, D. M., Cornish, J. W., Lynch, K. G., Boney, T. Y., Clark, C. A., Lee, J. D., … O’Brien, C. P. (2012). A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse, 33(1), 48–59. doi:10.1080/08897077.2011.609438
   PubMed Web of Science ®Google Scholar
• Crits-Christoph, P., Lundy, C., Stringer, M., Gallop, R., & Gastfriend, D. R. (2015). Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers. doi:10.1016/j.jsat.2015.03.003
   Google Scholar
• Egli, N., Pina, M., Skovbo Christensen, P., Aebi, M., & Killias, M. (2009). Effects of drug substitution programs on offending among drug-addicts. (Systematic Review No. 3). Oslo, Norway: Campbell Systematic Reviews.
   Google Scholar
• Finigan, M. W., Perkins, T., Sullivan, J. E., & Kandrevas, J. A. (2014). Is there a role for extended-release naltrexone in drug courts? Results of a pilot study. Drug Court Review, IX(1), 23–42.
   Google Scholar
• Finigan, M. W., Perkins, T., Zold-Kilbourn, P., Parks, J., & Stringer, M. (2011). Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. Journal of Substance Abuse Treatment, 41(3), 288–293. doi:10.1016/j.jsat.2011.04.003
   PubMed Web of Science ®Google Scholar
• Frank, R. G., Beronio, K., & Glied, S. A. (2014). Behavioral health parity and the affordable care act. Journal of Social Work in Disability & Rehabilitation, 13, 31–43. doi:10.1080/1536710X.2013.870512
   PubMedGoogle Scholar
• Friedman, S., & Wagner-Goldstein, K. (2015). Medication-assisted treatment in drug courts. Recommended strategies. New York State: Legal Action Center, Center for Court Innovation.
   Google Scholar
• Friedmann, P. D., Andrews, C. M., & Humphreys, K. (2017). How ACA repeal would worsen the opioid epidemic. New England Journal of Medicine, 376(10), e16. doi:10.1056/NEJMp1700834
   PubMed Web of Science ®Google Scholar
• Friedmann, P. D., Hoskinson, R., Gordon, M., Schwartz, R., Kinlock, T., & Knight, K., MAT Working Group Of CJ-DATS. (2012). Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers, and intentions. Substance Abuse, 33(1), 9–18. doi:10.1080/08897077.2011.611460
   PubMed Web of Science ®Google Scholar
• Gallagher, J. R., Nordberg, A., Deranek, M. S., Ivory, E., Carlton, J., & Miller, J. W. (2015). Predicting termination from drug court and comparing recidivism patterns: Treating substance use disorders in criminal justice settings. Alcoholism Treatment Quarterly, 33(1), 28–43. doi:10.1080/07347324.2015.982451
   Web of Science ®Google Scholar
• Gerra, G., Maremmani, B., Capovani, L., Somaini, S., Berterame, J., Tomas-Rossello, E., … Kleber, H. (2009). Long-acting opioid-agonists in the treatment of heroin addiction: Why should we call them “substitution”? Substance Use & Misuse, 44, 663–671. doi:10.1080/10826080902810251
   PubMed Web of Science ®Google Scholar
• Gill, M. E. (2016). Predictors of drug court client graduation. Journal of Offender Rehabilitation, 55(8), 564–588. doi:10.1080/10509674.2016.1229710
   Web of Science ®Google Scholar
• Gordon, M. S., Kinlock, T. W., Vocci, F. J., Fitzgerald, T. T., Memisoglu, A., & Silverman, B. (2015). A phase 4, pilot, open-label study of VIVITROL® (extended-release naltrexone XR-NTX) for prisoners. doi:10.1016/j.jsat.2015.07.005
   Google Scholar
• Gray, A. R., & Saum, C. A. (2005). Mental health, gender, and drug court completion. American Journal of Criminal Justice, 30(1), 55–69. doi:10.1007/BF02885881
   Google Scholar
• Gryczynski, J., Kinlock, T. W., Kelly, S. M., O’Grady, K. E., Gordon, M. S., & Schwartz, R. P. (2012). Opioid agonist maintenance for probationers: Patient-level predictors of treatment retention, drug use, and crime. Substance Abuse, 33(1), 30–39. doi:10.1080/08897077.2011.616816
   PubMed Web of Science ®Google Scholar
• IBM Corp. (2013). IBM SPSS statistics for windows, version 22.0. Armonk, NY: IBM Corp.
   Google Scholar
• Jones, C. M., Logan, J., Gladden, R. M., & Bohm, M. K. (2015). Vital signs: Demographic and substance use trends among heroin users — United States, 2002–2013. Morbidity and Mortality Weekly Report, 64(26), 719–725.
   PubMed Web of Science ®Google Scholar
• Kerrison, E. M. (2017). An historical review of racial bias in prison-based substance abuse treatment design. Journal of Offender Rehabilitation, 56(8), 567–592. doi:10.1080/10509674.2017.1363114
   Web of Science ®Google Scholar
• Kjome, K. L., & Moeller, F. G. (2011). Long-acting injectable naltrexone for the management of patients with opioid dependence. Substance Abuse: Research and Treatment, 5, 1–9. doi:10.4137/SART.S5452
   PubMedGoogle Scholar
• Koehler, J. A., Humphreys, D. K., Akoensi, T. D., Sánchez, D. R., & Lösel, F. (2014). A systematic review and meta-analysis on the effects of European drug treatment programmes on reoffending. Psychology, Crime & Law, 20(6), 584–602. doi:10.1080/1068316X.2013.804921
   Web of Science ®Google Scholar
• Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., … O’Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374(13), 1232–1242. doi:10.1056/NEJMoa1505409
   PubMed Web of Science ®Google Scholar
• Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. The Lancet, 391(10118), 309–318. doi:10.1016/S0140-6736(17)32812-X
   PubMed Web of Science ®Google Scholar
• Ling, W. (2009). Buprenorphine for opioid dependence. Expert Review of Neurotherapeutics, 9(5), 609–616. doi:10.1586/ern.09.26
   PubMed Web of Science ®Google Scholar
• Marlowe, D. B., Hardin, C. D., & Fox, C. L. (2016). Painting the current picture. A national report on drug courts and other problem-solving courts in the United States. (NADCP Report). Alexandria, VA: National Drug Court Institute. Retrieved from www.AllRise.org
   Google Scholar
• Matejkowski, J., Dugosh, K. L., Clements, N. T., & Festinger, D. S. (2015). Pilot testing of an online training for criminal justice professionals on medication-assisted treatment. Journal of Addictions & Offender Counseling, 36(1), 13–27. doi:10.1002/j.2161-1874.2015.00032.x
   Web of Science ®Google Scholar
• Matusow, H., Dickman, S. L., Rich, J. D., Fong, C., Dumont, D. M., Hardin, C., … Rosenblum, A. (2013). Medication assisted treatment in us drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of Substance Abuse Treatment, 44(5), 473–480. doi:10.1016/j.jsat.2012.10.004
   PubMed Web of Science ®Google Scholar
• McElrath, K. (2018). Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Substance Use & Misuse, 53(2), 334–343. doi:10.1080/10826084.2017.1342662
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., … Argeriou, M. (1992). The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment, 9(3), 199–213. doi:10.1016/0740-5472(92)90062-S
   PubMed Web of Science ®Google Scholar
• Mitchell, O., Wilson, D., Eggers, A., & MacKenzie, D. (2012). Drug courts’ effects on criminal offending for juveniles and adults. Campbell Systematic Reviews, 8(4), 86. doi:10.4073/csr.2012.4
   Google Scholar
• Mitchell, S. G., Willet, J., Monico, L. B., James, A., Rudes, D. S., Viglioni, J., … Friedmann, P. D. (2016). Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Substance Abuse, 37(1), 127–133. doi:10.1080/08897077.2015.1129389
   PubMed Web of Science ®Google Scholar
• Mollman, M., & Mehta, C. (2017). Neither justice nor treatment: Drug courts in the United States. Retrieved from http://physiciansforhumanrights.org/assets/misc/phr_drugcourts_report_singl
   Google Scholar
• Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018). Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 85, 90–96. doi:10.1016/j.jsat.2017.07.001
   Google Scholar
• Novick, D. M., Salsitz, E. A., Joseph, H., & Kreek, M. J. (2015). Methadone medical maintenance: An early 21st-century perspective. Journal of Addictive Diseases, 34(2–3), 226–237. doi:10.1080/10550887.2015.1059225
   PubMed Web of Science ®Google Scholar
• Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016). Increases in drug and opioid overdose deaths–United States, 2000-2014. MMWR: Morbidity & Mortality Weekly Report, 64(50), 1378–1382. doi:10.15585/mmwr.mm6450a3
   PubMed Web of Science ®Google Scholar
• Shannon, L. M., Jackson Jones, A., Perkins, E., Newell, J., & Neal, C. (2016). Examining individual factors and during-program performance to understand drug court completion. Journal of Offender Rehabilitation, 55(5), 271–292. doi:10.1080/10509674.2016.1181130
   Web of Science ®Google Scholar
• Strong, S. M., Rantala, R. R., & Kyckelhahn, T. (2016). Census of problem-solving courts, 2012. Retrieved from https://www.bjs.gov/content/pub/pdf/cpsc12.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2016). Decisions in recovery: Medications for opioid use disorder. [electronic decision support tool]. (No. HHS Pub No. SMA-16-4993). Rockville, MD.: Substance Abuse and Mental Health Services Administration. Retrieved from http://www.samhsa.gov/brss-tacs/shared-decision-making
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2017). Buprenorphine waiver management. Retrieved from https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management
   Google Scholar
• Taxman, F. S., & Bouffard, J. A. (2005). Treatment as part of drug court: The impact on graduation rates. Journal of Offender Rehabilitation, 42(1), 23–50. doi:10.1300/J076v42n01_02
   Google Scholar
• Volkow, N. D., & Collins, F. S. (2017). The role of science in addressing the opioid crisis. New England Journal of Medicine, 377(4), 391–394. doi:10.1056/NEJMsr1706626
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies - tackling the opioid-overdose epidemic. New England Journal of Medicine, 370(22), 2063–2066. doi:10.1056/NEJMp1402780
   PubMed Web of Science ®Google Scholar
• Warner, M., Trinidad, J. P., Bastian, B. A., Miniño, A. M., & Hedegaard, H. (2016). Drugs most frequently involved in drug overdose deaths: United states, 2010-2014. (National vital statistics reports No. 65). Hyattsville, MD.: National Center for Health Statistics. Retrieved from https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_10.pdf
   Google Scholar
• Wilson, D., Mitchell, O., & MacKenzie, D. (2006). A systematic review of drug court effects on recidivism. Journal of Experimental Criminology, 2(4), 459–487. doi:10.1007/s11292-006-9019-4
   Google Scholar